|
|
去水淫羊藿黄素市场分析报告
|
Global Market Report of NOR-ICARITIN (CAS 5240-95-9)
December 2024
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H1 2018
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H1 2018 SUMMARY Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Aryl hydrocarbon receptor is a protein ...
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H2 2017
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H2 2017 SUMMARY According to the recently published report 'Aryl Hydrocarbon Receptor - Pipeline Review, H2 2017'; Aryl Hydrocarbon Receptor (Class ...
Vascular Disrupting Agents Market, 2021-2030: Distribution by Target Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Hepatocellular Carcinoma, Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer, Prostate Cancer, Recurrent Platinum Resistant Ovarian Cancer, Transitional Cell Cancer of Renal Pelvis and Ureter), Therapeutic Area (Hematological Malignancies, Solid Tumors and Other Therapeutic Areas), Type of Molecule (Small Molecule (Tubulin Binding Agents and Flavonoids) and Ligand-Directed Agents) and Ligand-Directed Agents), Type of Therapy (Monotherapy, Combination Therapy And Both), Route of Administration (Oral, Intravenous), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)
The vascular disrupting agents market is expected to reach USD 23 million in 2021 and anticipated to grow at a CAGR of 65% during the forecast period 2021-2030. Solid tumors constitute roughly 90% of diagnosed cancer cases, driving extensive efforts ...
|
|
|
|
